412 related articles for article (PubMed ID: 27306074)
21. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
22. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
Battat R; Ma C; Jairath V; Khanna R; Feagan BG
Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
[TBL] [Abstract][Full Text] [Related]
23. Next-Generation Therapeutics for Inflammatory Bowel Disease.
Dulai PS; Sandborn WJ
Curr Gastroenterol Rep; 2016 Sep; 18(9):51. PubMed ID: 27461274
[TBL] [Abstract][Full Text] [Related]
24. Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
Tepeš K; Hanžel J; Štubljar D; Strmšek K; Erjavec L; Supovec E; Jagodic Z; Končan M; Grosek J; Košir JA; Tomažič A; Kogovšek U; Norčič G; Šibli R; Žnidaršič M; Pačnik Vižintin T; Sodin B; Breznik J; Hribar VA; Ocepek A; Pernat Drobež C; Bukovnik N; Zafošnik A; Marušič T; Jurečič Brglez N; Denkovski M; Smrekar N; Novak G; Koželj M; Kurent T; Simonič J; Pintar Š; Štabuc B; Drobne D
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):728-734. PubMed ID: 38625825
[TBL] [Abstract][Full Text] [Related]
25. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate for inflammatory bowel disease: time for reconsideration.
Nielsen OH; Ainsworth MA; Steenholdt C
Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
[No Abstract] [Full Text] [Related]
27. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.
Dalal RS; Ananthakrishnan AN; Hamilton MJ; Winter RW
Dig Dis Sci; 2021 Mar; 66(3):733-737. PubMed ID: 33569666
[No Abstract] [Full Text] [Related]
28. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Scribano ML
World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
[TBL] [Abstract][Full Text] [Related]
29. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
30. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
[TBL] [Abstract][Full Text] [Related]
32. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
[No Abstract] [Full Text] [Related]
33. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
34. Ustekinumab for Resistant Pediatric Crohn Disease.
Rinawi F; Rosenbach Y; Assa A; Shamir R
J Pediatr Gastroenterol Nutr; 2016 Apr; 62(4):e34-5. PubMed ID: 25023579
[No Abstract] [Full Text] [Related]
35. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
[TBL] [Abstract][Full Text] [Related]
36. Real-world evidence for vedolizumab: Understanding the landscape.
Lawrance IC; Pulusu SSR
J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():28-29. PubMed ID: 30187556
[No Abstract] [Full Text] [Related]
37. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
38. Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.
Conrad MA; Stein RE; Maxwell EC; Albenberg L; Baldassano RN; Dawany N; Grossman AB; Mamula P; Piccoli DA; Kelsen JR
Inflamm Bowel Dis; 2016 Oct; 22(10):2425-31. PubMed ID: 27598742
[TBL] [Abstract][Full Text] [Related]
39. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.
Van den Berghe N; Verstockt B; Tops S; Ferrante M; Vermeire S; Gils A
J Gastroenterol Hepatol; 2019 Jul; 34(7):1175-1181. PubMed ID: 30589948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
